| |
| |
|
| Insider
Information: |
Green Jeremy |
| Relationship: |
Former 10% Owner and D... |
| City: |
San Francisco |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
31 |
|
| Direct
Shares |
49,793 |
|
|
Indirect Shares
|
116,486,068 |
|
|
| Direct
Value |
$250,957 |
|
|
|
Indirect Value
|
$340,999,325 |
|
|
| Total
Shares |
116,535,861 |
|
|
| Total
Value |
$341,250,282 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
9
|
1
|
|
Stock
price went up :
|
2
|
0
|
| Stock
price went down : |
7
|
1
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
-1.0
|
| Percentage
Gain/Loss : |
 -15.3%
|
-38.6%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Amicus Therapeutics Inc |
FOLD |
10% Owner |
2016-06-03 |
0 |
2016-06-03 |
12,956,446 |
Premium* |
|
|
Syros Pharmaceuticals, Inc. |
SYRS |
10% Owner |
2016-07-06 |
49,793 |
2016-07-06 |
0 |
Premium* |
|
|
Xeris Pharmaceuticals Inc |
XERS |
10% Owner |
2018-06-25 |
0 |
2019-02-19 |
3,000,642 |
Premium* |
|
|
Allakos Inc. |
ALLK |
10% Owner |
2018-07-23 |
0 |
2018-07-23 |
1,009,090 |
Premium* |
|
|
Replimune Group Inc |
REPL |
10% Owner |
2018-07-24 |
0 |
2018-07-24 |
779,655 |
Premium* |
|
|
Fate Therapeutics Inc |
FATE |
Director, 10% Owner |
2018-09-25 |
0 |
2023-12-26 |
13,180,388 |
Premium* |
|
|
Gritstone Oncology, Inc. |
GRTS |
10% Owner |
2018-10-02 |
0 |
2018-10-02 |
1,394,529 |
Premium* |
|
|
Vapotherm Inc |
VAPO |
10% Owner |
2018-11-16 |
0 |
2018-11-16 |
959,540 |
Premium* |
|
|
Tcr2 Therapeutics Inc. |
TCRR |
10% Owner |
2019-02-19 |
0 |
2019-02-19 |
807,256 |
Premium* |
|
|
Alder Biopharmaceuticals Inc |
ALDR |
Director |
2019-03-04 |
0 |
2019-10-22 |
0 |
Premium* |
|
|
Akero Therapeutics, Inc. |
AKRO |
10% Owner |
2019-06-24 |
0 |
2019-06-24 |
743,802 |
Premium* |
|
|
Atreca Inc |
BCEL |
10% Owner |
2019-06-24 |
0 |
2019-06-24 |
715,306 |
Premium* |
|
|
Stoke Therapeutics, Inc. |
STOK |
10% Owner |
2019-06-21 |
0 |
2019-06-21 |
671,808 |
Premium* |
|
|
Igm Biosciences, Inc. |
IGMS |
10% Owner |
2019-09-20 |
0 |
2024-03-29 |
3,078,332 |
Premium* |
|
|
Aprea Therapeutics, Inc. |
APRE |
10% Owner |
2019-10-07 |
0 |
2020-12-28 |
1,768,718 |
Premium* |
|
|
Cabaletta Bio, Inc. |
CABA |
10% Owner |
2019-10-29 |
0 |
2019-10-29 |
696,378 |
Premium* |
|
|
Beam Therapeutics Inc. |
BEAM |
10% Owner |
2020-02-10 |
0 |
2020-02-10 |
1,161,458 |
Premium* |
|
|
Neurogene |
NGNE |
10% Owner |
2020-03-27 |
0 |
2020-04-02 |
4,041,211 |
Premium* |
|
|
Pliant Therapeutics, Inc. |
PLRX |
10% Owner |
2020-06-05 |
0 |
2020-06-05 |
1,910,657 |
Premium* |
|
|
Repare Therapeutics Inc. |
RPTX |
10% Owner |
2020-06-23 |
0 |
2020-06-23 |
1,586,174 |
Premium* |
|
|
Nurix Therapeutics, Inc. |
NRIX |
10% Owner |
2020-07-28 |
0 |
2020-07-28 |
1,176,470 |
Premium* |
|
|
Annexon, Inc. |
ANNX |
10% Owner |
2020-07-28 |
0 |
2020-07-28 |
1,596,222 |
Premium* |
|
|
Allovir Inc |
ALVR |
10% Owner |
2020-08-03 |
0 |
2020-08-03 |
823,371 |
Premium* |
|
|
Kymera Therapeutics, Inc. |
KYMR |
10% Owner |
2020-08-25 |
0 |
2020-08-25 |
1,630,660 |
Premium* |
|
|
Augmedix, Inc |
AUGX |
Director, 10% Owner |
2020-10-05 |
0 |
2024-03-15 |
16,408,909 |
Premium* |
|
|
Shattuck Labs, Inc. |
STTK |
Director, 10% Owner |
2020-10-14 |
0 |
2024-03-28 |
5,615,489 |
Premium* |
|
|
MedAvail Holdings, Inc |
MDVL |
Director, 10% Owner |
|
0 |
2022-04-04 |
25,192,751 |
Premium* |
|
|
Verve Therapeutics, Inc. |
VERV |
10% Owner |
2021-06-21 |
0 |
2021-06-21 |
1,936,530 |
Premium* |
|
|
Absci Corp |
ABSI |
Director |
2021-07-26 |
0 |
2024-03-01 |
8,253,316 |
Premium* |
|
|
Adagio Therapeutics, Inc. |
ADGI |
10% Owner |
2021-08-10 |
0 |
2021-08-10 |
3,390,960 |
Premium* |
|
|
Science 37 Holdings, Inc |
SNCE |
Former 10% Owner and D... |
2021-10-06 |
0 |
2024-03-12 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| IGMS |
Igm Biosciences, Inc. |
10% Owner |
– – • |
2024-03-29 |
4 |
A |
$0.00 |
$0 |
I/I |
1,734 |
3,078,332 |
0 |
- |
|
| IGMS |
Igm Biosciences, Inc. |
10% Owner |
– – • |
2024-03-28 |
4 |
D |
$0.00 |
$0 |
I/I |
(12,464) |
3,076,598 |
0 |
- |
|
| STTK |
Shattuck Labs, Inc. |
Director |
– • • |
2024-03-28 |
4 |
D |
$0.00 |
$0 |
I/I |
(4,425) |
5,615,489 |
0 |
- |
|
| AUGX |
Augmedix, Inc |
Director |
– • • |
2024-03-15 |
4 |
A |
$0.00 |
$0 |
I/I |
3,125 |
16,408,909 |
0 |
- |
|
| SNCE |
Science 37 Holdings, Inc |
Former 10% Owner and Director |
– – – |
2024-03-12 |
4 |
D |
$5.75 |
$5,848,917 |
I/I |
(1,017,203) |
0 |
0 |
- |
|
| ABSI |
Absci Corp |
Director |
– • – |
2024-03-01 |
4 |
B |
$4.50 |
$999,999 |
I/I |
222,222 |
8,253,316 |
2.1 |
% |
|
| IGMS |
Igm Biosciences, Inc. |
10% Owner |
– – • |
2024-02-28 |
4 |
A |
$0.00 |
$0 |
I/I |
113,400 |
3,089,062 |
0 |
- |
|
| IGMS |
Igm Biosciences, Inc. |
Director |
– • – |
2023-12-29 |
4 |
A |
$0.00 |
$0 |
I/I |
492 |
2,975,662 |
0 |
- |
|
| FATE |
Fate Therapeutics Inc |
Director |
– • • |
2023-12-26 |
4 |
B |
$3.72 |
$166,024 |
I/I |
44,630 |
13,180,388 |
2.25 |
% |
|
| FATE |
Fate Therapeutics Inc |
Director |
– • • |
2023-12-26 |
4 |
D |
$3.72 |
$6,157,976 |
I/I |
(1,655,370) |
13,135,758 |
0 |
- |
|
| FATE |
Fate Therapeutics Inc |
Director |
– • • |
2023-12-26 |
4 |
A |
$3.72 |
$6,157,976 |
I/I |
1,655,370 |
13,135,758 |
0 |
- |
|
| AUGX |
Augmedix, Inc |
Director |
– • • |
2023-12-15 |
4 |
A |
$0.00 |
$0 |
I/I |
1,767 |
16,405,784 |
0 |
- |
|
| IGMS |
Igm Biosciences, Inc. |
Director |
– • – |
2023-09-29 |
4 |
A |
$0.00 |
$0 |
I/I |
492 |
2,975,170 |
0 |
- |
|
| AUGX |
Augmedix, Inc |
Director |
– • • |
2023-08-31 |
4 |
A |
$4.78 |
$10,000 |
I/I |
2,092 |
15,654,017 |
0 |
- |
|
| AUGX |
Augmedix, Inc |
Director |
– • • |
2023-07-13 |
4 |
A |
$0.00 |
$0 |
I/I |
21,598 |
15,651,925 |
0 |
- |
|
| IGMS |
Igm Biosciences, Inc. |
Director |
– • – |
2023-06-30 |
4 |
A |
$0.00 |
$0 |
I/I |
492 |
2,974,678 |
0 |
- |
|
| IGMS |
Igm Biosciences, Inc. |
Director |
– • – |
2023-06-29 |
4 |
S |
$9.42 |
$757,585 |
I/I |
(80,423) |
2,893,763 |
0 |
- |
|
| IGMS |
Igm Biosciences, Inc. |
Director |
– • – |
2023-06-29 |
4 |
B |
$9.42 |
$757,585 |
I/I |
80,423 |
2,974,186 |
2.1 |
- |
|
| IGMS |
Igm Biosciences, Inc. |
Director |
– • – |
2023-06-29 |
4 |
D |
$9.42 |
$515,651 |
I/I |
(54,740) |
2,919,446 |
0 |
- |
|
| IGMS |
Igm Biosciences, Inc. |
Director |
– • – |
2023-06-29 |
4 |
A |
$9.42 |
$515,651 |
I/I |
54,740 |
2,974,186 |
0 |
- |
|
| SNCE |
Science 37 Holdings, Inc |
Director |
– • • |
2023-05-11 |
4 |
A |
$0.25 |
$125,000 |
I/I |
494,853 |
20,344,070 |
0 |
- |
|
| FATE |
Fate Therapeutics Inc |
Director |
– • • |
2023-04-21 |
4 |
B |
$6.18 |
$1,586,029 |
I/I |
256,639 |
13,135,758 |
2.25 |
% |
|
| FATE |
Fate Therapeutics Inc |
Director |
– • • |
2023-04-20 |
4 |
B |
$5.99 |
$119,800 |
I/I |
20,000 |
12,879,119 |
2.25 |
% |
|
| AUGX |
Augmedix, Inc |
Director |
– • • |
2023-04-19 |
4 |
A |
$1.60 |
$2,000,000 |
I/I |
1,250,000 |
15,630,327 |
0 |
- |
|
| FATE |
Fate Therapeutics Inc |
Director |
– • • |
2023-04-14 |
4 |
A |
$5.84 |
$32,075,528 |
I/I |
5,492,385 |
12,833,419 |
0 |
- |
|
25 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
